Unfortunately, our Chief Medical Officer, Dr. Lori Kunkel, cannot join us today due to a family vacation, which she has unfortunately no phone access so Dr. Jesse McGreivy will jump in and will provide the clinical update.
Our agenda for today's call will focus on the accomplishments we have achieved organizationally, the team we have built up here at the company and accomplishments within our partnership with Janssen. We will summarize the clinical initiations and achievements, and we will also provide a clinical outlook of what to expect by year end.
Let me start with a summary of our financial results. Revenue for the fiscal year ended June 30, 2012, was $82 million compared to $8.2 million for the fiscal year ended June 30, 2011, an increase of $73.8 million.
The non-GAAP net income reported for the fiscal year ended June 30, 2012, was $21.9 million or $0.32 per basic and $0.30 per diluted share. This compares with the non-GAAP not less -- net loss of $28 million or $0.47 loss per share for the fiscal year ended June 30, 2011.For the quarter ended June 30, 2012, the non-GAAP net loss was $15.1 million or $0.22 per share, which compares with a non-GAAP net loss of $9.1 million or $0.15 per share for 2011 -- for the 2011 quarter.The GAAP net income for the fiscal year ended June 30, 2012, was $12 million or $0.17 per basic and diluted share. This compares with a GAAP net loss of $35.2 million or $0.59 per share for the year ended June 30, 2011. For the quarter ended June 30, 2012, the GAAP net loss was $16.9 million or $0.24 loss per share. This compares with a GAAP net loss of $11 million or $0.18 loss per share for the fiscal quarter ended June 30, 2011.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV